Lv1
70 积分 2023-11-28 加入
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
1天前
已完结
Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma
4天前
已关闭
Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer
18天前
已关闭
Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors
18天前
已完结
572P Real-world outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: First multicenter results from Taiwan
20天前
已关闭
HER2 and urothelial carcinoma: current understanding and future directions
1个月前
已完结
Antibody–drug conjugates in urothelial carcinoma: current status and future
1个月前
已完结
Comparative Adverse Effect Profiles of Platinum Drugs
1个月前
已完结
Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial
4个月前
已完结
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
4个月前
已完结
皖公网安备34019202002308
